The Administrative Core (AC) serves as the central coordinating center that manages and integrates the multiple program activities carried out at the ADCS and co-located facilities, and is necessary to maintain smooth operation of this complex grant program. Because the AC activities integrate with the activities of each of the other ADCS cores and committees it results in a multi-faceted approach that lends itself to communication and information sharing among all cores. The primary objective of the AC is to provide overall direction and oversight to the ADCS by working closely with its various cores and committees to accomplish program goals. The ADCS is a large, complex organization, with over 100 members at UCSD, 8 cores, 35 primary performance sites, dozens of additional sites, multiple ongoing trials, collaborations with multiple companies, and contracts with many vendors. It is primarily an academic organization, but performs all of the activities required by multicenter trials, with an in-house data management system, biostatistics, clinical operations, regulatory oversight, medical and safety management, and onsite and remote clinical monitoring. Smooth operation requires, in addition to experience and expertise, efficient and effective management, standard operating procedures and quality assurance programs, and effective communications. The standing committees, which exist throughout the grant period, contribute to all grant activities. The Committees budgeted within the Administrative Core are the Internal Ethics Committee, the Clinical Dementia Rating Scale Committee, and the Instrument Committee with its five subcommittees.
There is no greater health care need than the development of effective therapy for AD. With aging baby-boomers now at the age of risk for AD, the epidemic will accelerate. The ADCS maintains an optimized infrastructure to support its trials, as well as trials and longitudinal studies funded by other grants, and to facilitate sharing of data, specimens and methods.
|Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358|
|Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431|
|Buckley, Rachel F; Mormino, Elizabeth C; Amariglio, Rebecca E et al. (2018) Sex, amyloid, and APOE ?4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement 14:1193-1203|
|Sawda, Christine; Moussa, Charbel; Turner, R Scott (2017) Resveratrol for Alzheimer's disease. Ann N Y Acad Sci 1403:142-149|
|Buckley, R F; Sparks, K P; Papp, K V et al. (2017) Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries. J Prev Alzheimers Dis 4:3-11|
|Raman, Mekala R; Tosakulwong, Nirubol; Zuk, Samantha M et al. (2017) Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. J Hypertens 35:2479-2485|
|Respondek, Gesine; Kurz, Carolin; Arzberger, Thomas et al. (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995-1005|
|Rentz, Dorene M; Mormino, Elizabeth C; Papp, Kathryn V et al. (2017) Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav 11:383-390|
|Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145|
|Langa, Kenneth M; Larson, Eric B; Crimmins, Eileen M et al. (2017) A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 177:51-58|
Showing the most recent 10 out of 490 publications